Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Betaloc: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Betaloc - General Information

A selective adrenergic beta-1-blocking agent with no stimulatory action. It&

 

Pharmacology of Betaloc

Betaloc, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).

 

Betaloc for patients

Metoprolol succinate is used to treat high blood pressure alone or in combination with other medications. This medication can also be used to treat a heart condition called angina. This particular formulation is an extended release product, meaning it can be taken once a day. This medication should be taken as directed, with a meal or right after a meal. The tablets should not be broken or crushed. Do not take a double dose if a dose is missed. This medication should not be stopped abruptly; it should be discontinued slowly over time. If you are taking this medication for high blood pressure, make sure to have your blood pressure checked regularly. If you ever have trouble breathing, call your physician immediately. The most common adverse effects are dizziness and tiredness. It is important to inform all your healthcare providers that you are taking this medication, especially before any surgeries or procedures.

 

Betaloc Interactions

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with extended release metoprolol succinate plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

 

Betaloc Contraindications

Hypertension and Angina: Extended release metoprolol succinate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure

 

Additional information about Betaloc

Betaloc Indication: For the treatment of hypertension and angina pectoris. Mechanism Of Action: Like betaxolol and atenolol, metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure. Drug Interactions: Acetohexamide The beta-blocker decreases the symptoms of hypoglycemia Chlorpropamide The beta-blocker decreases the symptoms of hypoglycemia Cimetidine Cimetidine increases the effect of the beta-blocker Clonidine Increased hypertension when clonidine stopped Disopyramide The beta-blocker increases toxicity of disopyramide Gliclazide The beta-blocker decreases the symptoms of hypoglycemia Glipizide The beta-blocker decreases the symptoms of hypoglycemia Glisoxepide The beta-blocker decreases the symptoms of hypoglycemia Glibenclamide The beta-blocker decreases the symptoms of hypoglycemia Glycodiazine The beta-blocker decreases the symptoms of hypoglycemia Insulin The beta-blocker decreases the symptoms of hypoglycemia Lidocaine The beta-blocker increases the effect and toxicity of lidocaine Propafenone Propafenone increases the effect of beta-blocker Repaglinide The beta-blocker decreases the symptoms of hypoglycemia Rifampin Rifampin decreases the effect of the metabolized beta-blocker Telithromycin Telithromycin may possibly increase metoprolol effect Tolazamide The beta-blocker decreases the symptoms of hypoglycemia Tolbutamide The beta-blocker decreases the symptoms of hypoglycemia Amobarbital The barbiturate decreases the effect of metabolized beta-blocker Aprobarbital The barbiturate decreases the effect of metabolized beta-blocker Butalbital The barbiturate decreases the effect of metabolized beta-blocker Butabarbital The barbiturate decreases the effect of metabolized beta-blocker Butethal The barbiturate decreases the effect of metabolized beta-blocker Dihydroquinidine barbiturate The barbiturate decreases the effect of metabolized beta-blocker Heptabarbital The barbiturate decreases the effect of metabolized beta-blocker Hexobarbital The barbiturate decreases the effect of metabolized beta-blocker Methohexital The barbiturate decreases the effect of metabolized beta-blocker Methylphenobarbital The barbiturate decreases the effect of metabolized beta-blocker Pentobarbital The barbiturate decreases the effect of metabolized beta-blocker Phenobarbital The barbiturate decreases the effect of metabolized beta-blocker Primidone The barbiturate decreases the effect of metabolized beta-blocker Quinidine barbiturate The barbiturate decreases the effect of metabolized beta-blocker Secobarbital The barbiturate decreases the effect of metabolized beta-blocker Talbutal The barbiturate decreases the effect of metabolized beta-blocker Citalopram The SSRI increases the effect of the beta-blocker Escitalopram The SSRI increases the effect of the beta-blocker Fluoxetine The SSRI increases the effect of the beta-blocker Sertraline The SSRI increases the effect of the beta-blocker Paroxetine The SSRI increases the effect of the beta-blocker Dihydroergotamine Ischemia with risk of gangrene Dihydroergotoxine Ischemia with risk of gangrene Ergonovine Ischemia with risk of gangrene Ergotamine Ischemia with risk of gangrene Methysergide Ischemia with risk of gangrene Verapamil Increased effect of both drugs Hydralazine Increased effect of both drugs Diltiazem Increased risk of bradycardia Epinephrine Hypertension, then bradycardia Fenoterol Antagonism Formoterol Antagonism Isoproterenol Antagonism Orciprenaline Antagonism Pirbuterol Antagonism Prazosin Risk of hypotension at the beginning of therapy Procaterol Antagonism Salbutamol Antagonism Salmeterol Antagonism Terbutaline Antagonism Ibuprofen Risk of inhibition of renal prostaglandins Indomethacin Risk of inhibition of renal prostaglandins Piroxicam Risk of inhibition of renal prostaglandins Food Interactions: Avoid alcohol. Take with food. Avoid natural licorice. Generic Name: Metoprolol Synonyms: Metoprolol Tartrate; Metoprolol succinate Drug Category: Sympatholytics; Antihypertensive Agents; Antiarrhythmic Agents; Adrenergic Agents Drug Type: Small Molecule; Approved; Investigational Other Brand Names containing Metoprolol: Beloc; Betaloc; Lopressor HCT; Lopresor; Lopresoretic; Lopressor; Metroprolol; Prelis; Selo-Zok; Seloken; Selopral; Toprol; Toprol-XL; Absorption: Rapid and complete, 50% Toxicity (Overdose): LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice) Protein Binding: 12% Biotransformation: Primarily hepatic Half Life: 3-7 hours Dosage Forms of Betaloc: Solution Intravenous Liquid Intravenous Tablet, extended release Oral Tablet Oral Chemical IUPAC Name: 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical Formula: C15H25NO3 Metoprolol on Wikipedia: https://en.wikipedia.org/wiki/Metoprolol Organisms Affected: Humans and other mammals